Akoya Biosciences, Inc. (AKYA)

Market Cap	208.93M
Revenue (ttm)	79.38M
Net Income (ttm)	-73.04M
Shares Out	38.41M
EPS (ttm)	-1.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,858
Open	5.68
Previous Close	5.74
Day's Range	5.27 - 5.82
52-Week Range	5.27 - 16.57
Beta	0.89
Analysts	Strong Buy
Price Target	16.80 (+208.82%)
Earnings Date	May 8, 2023

About AKYA

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microar...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 16, 2021
• Employees: 369
• Stock Exchange: NASDAQ
• Ticker Symbol: AKYA

Financial Performance

In 2022, AKYA's revenue was $74.86 million, an increase of 36.31% compared to the previous year's $54.92 million. Losses were -$70.64 million, 59.2% more than in 2021.

Analyst Forecast

According to 5 analysts, the average rating for AKYA stock is "Strong Buy." The 12-month stock price forecast is $16.8, which is an increase of 208.82% from the latest price.

Price Target

$16.8

(208.82% upside)

Analyst Consensus: Strong Buy